Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec 10;38(35):4131-4134.
doi: 10.1200/JCO.20.02668. Epub 2020 Oct 8.

Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality

Andrew M Evens  1 , Susan K Parsons  2
Affiliations
Editorial

Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality

Andrew M Evens et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Figures

FIG 1.
FIG 1.
Data sources to study the continuum of care for Hodgkin lymphoma. Ideal information to study morbidity health-related quality of life (HRQL), and mortality across the lifelong time horizon for patients with classic Hodgkin lymphoma (cHL) is not available from a single source of data. Clinical trials typically examine shorter-term efficacy (3-5 years) and acute on-study adverse events (AEs). Most clinical trials do not track AEs or morbidity that occur post-therapy, which leads to critical data gaps. Cancer registries and survivorship cohorts comprise real-world data that provide important insights with longer-term follow-up for morbidity, HRQL, and excess mortality that manifest after cHL therapy, including postacute outcomes (ie, 1-10 years after diagnosis).
See this image and copyright information in PMC

Comment on

References

    1. Hokland P, Shah M, David K, et al. doi: 10.1111/bjh.16587. How I treat advanced Hodgkin lymphoma - a global view. Br J Haematol . [epub ahead of print on June 19, 2020] - DOI - PMC - PubMed
    1. Longley J, Johnson PWM. Current treatment paradigms for advanced stage Hodgkin lymphoma. Br J Haematol. 2019;184:60–71. - PubMed
    1. Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: Limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134:1238–1246. - PMC - PubMed
    1. Depaus J, Delcourt A, André M. Therapeutic recommendations for early stage Hodgkin lymphomas. Br J Haematol. 2019;184:9–16. - PubMed
    1. Hanly P, Soerjomataram I, Sharp L. Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe. Int J Cancer. 2015;136:E136–E145. - PubMed